David R. Patton

National Cancer Institute — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

27h-index3.6kcitations220works1.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(59), Colorectal Cancer Treatments and Studies(43), Genetic factors in colorectal cancer(39), Lung Cancer Treatments and Mutations(33), Advanced Breast Cancer Therapies(20)

Publications220 total

Galaxy mergers in UNIONS – II. Predicting time-scales in the post-merger regime
Monthly Notices of the Royal Astronomical Society·2026Open Access
Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2.
Clinical Cancer Research·2026
TiNy Titans H <scp>I</scp> : Discovering Satellites via H <scp>I</scp> Gas in an Isolated, Compact Group of Dwarf Galaxies
The Astrophysical Journal·2026Open Access
Galaxy Mergers in UNIONS -- II: Predicting Timescales in the Post-Merger Regime
arXiv (Cornell University)·2026Open Access
Galaxy Mergers in UNIONS -- II: Predicting Timescales in the Post-Merger Regime
ArXiv.org·2026Open Access
Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i> <sup> <i>V600E</i> </sup> Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H
JCO Precision Oncology·2026Open Access
Larotrectinib in Patients With Tumors With <i>NTRK</i> Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1E
JCO Precision Oncology·2026Open Access
TiNy Titans HI: Discovering Satellites via HI Gas in an Isolated, Compact Group of Dwarf Galaxies
arXiv (Cornell University)·2025Open Access
Supplementary Figure 3 from Ipatasertib in Patients with Tumors with &lt;i&gt;AKT&lt;/i&gt; Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Figure 1 from Ipatasertib in Patients with Tumors with &lt;i&gt;AKT&lt;/i&gt; Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Table 1 from Ipatasertib in Patients with Tumors with &lt;i&gt;AKT&lt;/i&gt; Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Figure 2 from Ipatasertib in Patients with Tumors with &lt;i&gt;AKT&lt;/i&gt; Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Data from Ipatasertib in Patients with Tumors with &lt;i&gt;AKT&lt;/i&gt; Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Table 3 from Ipatasertib in Patients with Tumors with &lt;i&gt;AKT&lt;/i&gt; Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Data 1 from Ipatasertib in Patients with Tumors with &lt;i&gt;AKT&lt;/i&gt; Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Table 2 from Ipatasertib in Patients with Tumors with &lt;i&gt;AKT&lt;/i&gt; Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Table S1 from Phase II Study of Palbociclib (PD-0332991) in &lt;i&gt;CCND1&lt;/i&gt;, &lt;i&gt;2&lt;/i&gt;, or &lt;i&gt;3&lt;/i&gt; Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
2025Open Access
supplementary table TS1 from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
2025Open Access
Phase II Study of Vismodegib in Patients With <i>SMO-</i> or <i>PTCH1</i> -Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T
JCO Precision Oncology·2025
Germline Cancer Predisposition Results From the National Cancer Institute—Children's Oncology Group Pediatric MATCH Trial
JCO Precision Oncology·2025Open Access
page 1 of 11Next →

Frequent Co-authors

Lyndsay N. Harris(25), Lisa M. McShane(24), Keith T. Flaherty(23), Robert J. Gray(23), Stanley R. Hamilton(23), P. Mickey Williams(23), Larry Rubinstein(22), Peter J. O’Dwyer(22), Barbara A. Conley(22), Edith P. Mitchell(21), Carlos L. Arteaga(21), Shuli Li(17), James A. Zwiebel(17), Alice P. Chen(15), Brent Coffey(11), James V. Tricoli(10), Leo I. Gordon(8), Naoko Takebe(7), Richard F. Little(7), Jane N. Winter(7)